Carolina Ibanez Ibanez

Dr. Carolina Ibanez Ibanez

Pediatrics, Universidad de Chile, Santiago, Región Metropolitana, Chile
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Revista chilena de infectología
Verified
Journal Article
Open access
PDF file
Carolina Ibanez IbanezCarolina Ibanez Ibanez
Carolina Ibanez Ibanez
JTJuan Pablo Torres
Juan Pablo Torres
MSMaria Elena Santolaya
Maria Elena Santolaya
La enfermedad por coronavirus 2019, causada por el virus SARS-CoV2, fue declarada pandemia en marzo de 2020 por la OMS. La proteína S, de la superficie viral ha sido identificada como antígeno óptimo para el desarrollo de vacunas. En pandemia, el proceso tradicional de desarrollo de vacunas ha debido acelerarse para avanzar en una respuesta adecuada al problema, acortando los tiempos. La seguridad, inmunogenicidad, protección frente a la infección, fenómeno de “aumento dependiente de anticuerpos”, duración de la protección se estudian en paralelo, a diferencia de la manera tradicional en que se llevaba a cabo en etapas sucesivas. Actualmente en Fase III hay 4 tipos vacunas: inactivadas; en base a proteínas purificadas o recombinantes, en base a ácidos nucleicos ADN/ARN y en base a vectores virales. El objetivo de esta revisión es conocer los estudios que preceden a las vacunas que actualmente están en estudios de Fase III y describir las características principales de estos estudios. Actualmente el mundo se encuentra en una situación inédita en el último siglo. Dentro las opciones para enfrentar este hecho, una vacuna o idealmente varias, seguras, eficaces e inmunogénicas, parecen ser una de las mejores alternativas para retomar en un plazo razonable la normalidad perdida.

11 October 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
Carolina Ibanez IbanezCarolina Ibanez Ibanez
Carolina Ibanez Ibanez
JTJuan Pablo Torres
Juan Pablo Torres
VMVerónica De La Maza
Verónica De La Maza
SRSalome Rivera
Salome Rivera
RVRomina Valenzuela
Romina Valenzuela
MSMaria Elena Santolaya
Maria Elena Santolaya
Background: Bacterial bloodstream infections are a major cause of morbidity and mortality in children with cancer and episodes of fever and neutropenia (FN). The aim of this study was to evaluate the clinical outcome in children with cancer with 2 or more microorganisms isolated from blood cultures during their episodes of FN. Methods: Between 2016 and 2021, children presenting with high-risk FN, admitted to any of the 6 participating hospitals in Santiago, Chile, were included in this study if they have positive blood cultures. We compared the clinical outcome of children with 2 or more microorganisms versus those with single agent isolation. Results: A total of 1074 episodes of high-risk FN were enrolled in the study period, of which 27% (298) had positive blood cultures and 3% (32) had 2 or more microorganisms isolated from blood cultures. The most frequent identified agents were Viridans group streptococci and Escherichia coli in 20%, followed by Coagulase negative staphylococci in 14%. Children with 2 or more microorganisms presented more days of fever (7 vs. 4 days, P = 0.02), needed longer courses of antimicrobial therapy (16 vs. 14 days, P = 0.04) and had higher mortality at day 30 (13% vs. 1%, P = 0.003). Conclusions: Children with cancer and FN with 2 or more microorganisms isolated from blood cultures had a worse clinical outcome than children with single agent isolation.

30 June 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
Carolina Ibanez IbanezCarolina Ibanez Ibanez
Carolina Ibanez Ibanez
DJDaniza Jaldin
Daniza Jaldin
RVRomina Valenzuela
Romina Valenzuela
VMVerónica Msc de la Maza
Verónica Msc de la Maza
LPLizbet Pérez
Lizbet Pérez
MSMaria Elena Santolaya
Maria Elena Santolaya
Background: Febrile neutropenia (FN) is one of the most frequent complications of antineoplastic treatment in patients with cancer. Invasive bacterial infections and invasive fungal infections are a major cause of morbidity and mortality in this population, along with respiratory viral infections, which are increasingly recognized in children with FN episodes. Objectives: This study aimed to compare the clinical outcome of children with persistent high-risk FN (HRFN) that have an abnormal chest computed tomography (CT) versus those with normal chest CT or in which chest CT was not indicated, and to evaluate the microbiologic etiology and pulmonary tomographic findings in this population. Methods: Patients with persistent HRFN were prospectively enrolled between 2016 and 2021 and classified into 2 groups: children with persistent HRFN that had an abnormal chest CT and children that had a normal chest CT or in which chest CT was not clinically indicated. We compared the clinical outcome of the patients of the 2 groups. Children with abnormal chest CT underwent a microbiologic and molecular study to evaluate the etiology of the pulmonary compromise. After discharge, all children with persistent HRFN that had an abnormal chest CT were evaluated by 2 groups of independent, blind investigators: 1 pediatric infectious disease specialist that classified the etiology of the pulmonary infiltrate as bacterial, fungal, viral or unknown etiology and 2 pediatric radiologists that classified each chest CT, as defined by the Fleischner Society. Results: We enrolled 176 children with persistent HRFN, of which 36 had abnormal chest CT. In 27/36 episodes (75%), the etiology was determined (12 bacterial, 8 viral and 7 fungal). Subjects with an abnormal chest CT had more days of fever, longer length of hospital stay, higher PICU admission, more use of mechanical ventilation, more oxygen requirement, longer periods of antibacterial and antifungal therapy. Chest CT showed no statistically significant differences when findings were compared by etiology of the episodes. Conclusions: Our results strongly support that abnormal findings on chest CT in children with persistent HRFN should be interpreted as a predictor of poor clinical outcome, as not as a marker of etiology.

1 September 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
ACA.J. Conde-Moreno
A.J. Conde-Moreno
FLF. Lopez
F. Lopez
AHAsunción Hervás-Morón
Asunción Hervás-Morón
TCT. Piquer Camanes
T. Piquer Camanes
AMA. Mendez
A. Mendez
CACarlos Jose Ferrer Albiach
Carlos Jose Ferrer Albiach
SBRT-SG 05 (ClinicalTrials.gov Identifier: NCT02192788) is a collaborative (SBRT-SG, GICOR and SEOR) prospective multicenter phase II trial testing SBRT and hormone therapy (HT) in oligometastatic prostate cancer patients. The hypothesis is that SBRT can control the macroscopic disease and HT the microscopic one, as well as to test in hormone-sensitive (HS) patients the pause of the HT after biochemical control is achieved and that Castration Resistant prostate cancer (CRPC) is not radioresistant prostate cancer, and SBRT can delay new systemic treatments.

9 March 2021 in ecancermedicalscience
Verified
Journal Article
Open access
PSPatricio Salas
Patricio Salas
MSMaria Eliana Solovera
Maria Eliana Solovera
FBFelipe Bannura
Felipe Bannura
MMMatias Muñoz-Medel
Matias Muñoz-Medel
MCMiguel Cordova-Delgado
Miguel Cordova-Delgado
HGHéctor Galindo
Héctor Galindo
Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series Patricio Salas1, Maria Eliana S